Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Kidney Cancer treatment details. Biologic therapy. Chemotherapy. Memorial Sloan-Kettering Cancer Center, New York, NY, United States

Survival: 18.8 months
Toxicity Grade: 4
Treatments: Biologic therapy
Country: United States
City/State/Province: New York, NY
Hospital: Memorial Sloan-Kettering Cancer Center
Journal: Link
Date: 9/2007

Patients: This phase I/II study involved seventy-one patients with stage IV renal cell carcinoma. Of these patients, 39 (55%) had prior therapy. The majority of patients (76%) were men, and the median age was 59, ranging from 35 to 80 years old.

Treatment: Patients were treated with the biological therapy interferon –alpha and then the chemotherapy drug temsirolimus.

Toxicity: The most common grade 3 and 4 events included leukopenia, asthenia, hypophosphatemia, anemia, and hypertriglyceridemia. One patient experienced grade 3 interstitial pneumonia. Adverse events leading to treatment with lower doses of temsirolimus occurred in 55% of the patients.

Results: The median overall survival of all patients was 18.8 months. Not all patients were treated with the same number of doses or amount of drugs; for patients that received the ‘recommended-dose’ the median overall survival was 22.1 months

Support: This study was supported by Wyeth, which makes and/or markets temsirolimus.

Correspondence: Dr. Robert J. Motzer

E-mail to a Friend Email Physician More Information